Research Topics
| Ola JunghardSummaryAffiliation: AstraZeneca R and D Publications
| Collaborators
|
Detail Information
Publications
The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trialsMichael Shaw
Park Nicollet Clinic and University of Minnesota Medical School, Minneapolis, MN 55416 2699, USA
Health Qual Life Outcomes 6:31. 2008....
Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trialsO Junghard
Dept. of Clinical Science, , Sweden
Scand J Gastroenterol 38:1197-9. 2003
The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pHOla Junghard
AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
Eur J Clin Pharmacol 58:453-8. 2002....
Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux diseaseOla Junghard
Biostatistics, AstraZeneca R and D, Molndal, Sweden
Value Health 11:765-70. 2008....
Responsiveness of measures of heartburn improvement in non-erosive reflux diseaseOla Junghard
Biostatistics, AstraZeneca R and D, Molndal, Sweden
Health Qual Life Outcomes 5:32. 2007..The aim of the study was to investigate the responsiveness of various treatment success variables in patients with symptoms of heartburn...
Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux diseaseOla Junghard
Biostatistics, AstraZeneca R and D, Molndal, Sweden
Eur J Gastroenterol Hepatol 19:555-60. 2007....
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UKPeter Wahlqvist
AstraZeneca R and D Molndal, Sweden
Pharmacoeconomics 20:279-87. 2002..Clinical studies have demonstrated that esomeprazole is superior to omeprazole for the acute treatment of reflux oesophagitis...
Factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux diseaseKároly R Kulich
AstraZeneca R and D Molndal, Molndal, Sweden
Qual Life Res 12:699-708. 2003..To test whether the original factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) can be replicated in Nordic patients and English speaking patients...
Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda studyE Bolling-Sternevald
Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden
Dig Dis 26:256-63. 2008..We aimed to determine gastrointestinal symptom fluctuation in an random adult population using a validated questionnaire assessing gastrointestinal symptoms...
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?E Bolling-Sternevald
Department of Biomedicine and Surgery, Linkoping, Sweden
Aliment Pharmacol Ther 18:117-24. 2003..The efficacy of proton pump inhibitors in functional dyspepsia is modest and the prognostic factors are almost unknown...
Self-administered symptom questionnaires in patients with dyspepsia and their yield in discriminating between endoscopic diagnosesE Bolling-Sternevald
Department of Biomedicine, Linköping Hospital, Linkoping, Sweden
Dig Dis 20:191-8. 2002..We aimed at evaluating whether specific gastrointestinal symptoms, identified by self-administered questionnaires, correlate with specific endoscopic diagnoses and discriminate organic from functional dyspepsia...
Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trialE Bolling-Sternevald
Dept of Biomedicine, Linkoping, Sweden
Scand J Gastroenterol 37:1395-402. 2002..The role of drug treatment remains controversial. The aim in this study was to evaluate the effect of omeprazole 20 mg twice daily (b.i.d) and to test methods for symptom assessment...
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategiesPeter Wahlqvist
AstraZeneca R and D Molndal, Sweden
Pharmacoeconomics 20:267-77. 2002....
Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?Elaine McColl
Centre for Health Services Research, School of Population and Health Sciences, University of Newcastle upon Tyne, 21 Claremont Place, Newcastle upon Tyne NE2 4AA, United Kingdom
Am J Gastroenterol 100:11-8. 2005..This study aimed to determine the extent of agreement between clinicians and patients regarding assessments of reflux symptom severity in patients with gastroesophageal reflux disease...
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteersClive H Wilder-Smith
Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
Digestion 68:184-8. 2003..To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers...
Standardization of surgical technique in antireflux surgery: the LOTUS Trial experienceStephen E A Attwood
Department of Surgery, Northumbria Healthcare, North Tyneside Hospital, Rake Lane, North Shields, NE29 8NH, United Kingdom
World J Surg 32:995-8. 2008..This study was designed to identify a methodology for standardization of surgical technique and to measure the effectiveness of this standardization...
